Atrial fibrillation in mild to moderate heart failure is independently associated with progressive pump failure death  by Dries, D.L. et al.
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~ Pmdlctlon of Oeath and Mode of Death In Patlenta 
(pt~) Wllh Advan¢~l Conget, tlvo I'leart Fallum (.CHF), 
Clues for  Optimal Soloction of Therap~utlc upùons 
E. Gror~~, M, Fitg~r,o, M. MangiavaCChi, E, Vilali, F, Oltva, B, Andrauz,=~, 
G, Com~no, G. M~~"~¢co, 1", ~ .+:'o, P. Bal1~l~ t , A. Pollegrll+L "A. De 
C.a~~* C~rdi~c $~~g~q/ and Ca~ Center= H~rt Fa~lum am1 
C ,~~ ~ n t  P r~m,  Nt~rd~ Ca' Granda Ho~M, Mffan, Italy: 
~~t¢" . t~:  Pmd~mùPt ol lhe ~sk of ~kaath and ot the mode of death in 
pts with serum CHF iS cm:tal lot Ol~irl~l ~ t ~  Of h~gh,¢Ot~t thor4poul¢ 
~ :  ~ pts wlth ~wem CHF mferl'~! m OW Centee f~ ~aft~f~n 
fm heart ~ t m n  (Hlrx) wem dw~ on me basts of outceme, and 
their c l i t t ,  theJalPeUt~, t~oh~,  @t  heaft haemody~am~ (on OPtimal 
thera~), ~k  VO2~ aed echoca~~g~ptù¢ aha~nst~cs wem ~red  
among graues wah d~~ 
P, ~Su/ts." Tolal ~unnval at orte year was ~',~ (~an foltow ~p 45 months), 
Most ol lhe 1~4S who ~ had been evaluated dunng m - ~  s~ay because 
ol fe t ra~ CHF (61 out of 240 pls wrlP, ho~ admittance), while oldy 
t ~  0tl~tta*l!a ~ (B s l~  i/ealt~: SD). "Themfom, hosp~tahzatmn 
was ttm m~t pmmmmt dm+tal ~ at ~ st~tllng et' obsetvatm. Log+st+c 
mgmssm~ ~ m  was ~ fo I~'edat m ~  de,am (any (:ause) and 
~..ath w~m 1 ye-~r after ~he~ fO~ ~ ~  mod~ll!le~ ol (~~ath (CHF or 
SD). In, h0~al  a~,ath was mamly dehnt  on CHF progms~lon (30/35), 
and was p¢l~!K;ted by BUN (>80 mg,~(~), b~l~R~tn ( :. 1.35 mg/dl), Na" (< 135 
mEq4) at ~ and pers~le~ce of ~ W  rales ~3 daß after 
a~~~asm= L Oeath willen I year after disc~aq]e was due to enher CHF (14t26) 
or SD (12;26). Death duo to CHF was pm~cte¢l t,g yo~mg age, fow Na-, and 
eon-~-hem¢ etmfogy of fite disease; SD was pre~r~led by Iow can~ac ,m~x. 
and a n t ~  (syn~ptornat]c ventnoJ~a+ ant~as  or atnal fibnllatton] at 
achn(s~~on. 
~ :  ,Sens~tnt~y and SpeOfiC~t of the above ment;oned preoic- 
t~e modets should be chosen on the baSL~ of CUtTerd donor av~~lability, o
select tl~e approptmte herapeut~ Ophens. Pts at nsk for CHF death (i,~t~~ 
p~tl or after d~schan~e) sbeuld be co~sidered tor nmchantcal ass+st demce 
implantat+on, smce ~ tberal~' ~s ur~al~stadonl eren when acute de- 
compensabon m tempora~ reso~ed. Pts at nsk tot SD coufd take advantage 
by im0fanted caKhoverter*~efibnllator 
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~ Atrlal  Mi ld Moderate Heart Failure Is Fibril lation in to  
lndependenUy Asso¢iated WHh Progressive Pump 
Fai lure Death 
D.L. Dr=es, B.J. Gersh. M.J Domal~ski. LW Stevertson The National 
Hearf. Lung and Blood Inst~Pute, NIH. Be,.hesda, MD. George++own U ivers~ty 
HospRal, Wash«ngfon. DC, and The Bngham arm1Wornen+s Hosprtal, 
Bosto,~, MA. USA 
Backgtound: Atnal llbn~~ation (AF) has beet+ a~~ooated w~th incmased mof 
talily in some hut not all pre,Jious stud~.s in heart fadure. TI~ increased 
mortality in AF mtght be duo to excess deaths from Type I antiarrhylhm~c 
therapy, hut may also r~late tO an adverse impact of high heart rate and 
vawing R-R intervats on left ventncular (LV) function. 
Me!boris: We conducted a retrospectn~e anatysis O! the SOLVD Preven- 
tion and Tmatment Tnals parbcipants (N = 6,797) to determine =f AF fs 
independentty assooated with overall mortality and progressive heart failure 
deaths. A total of 419 participants had AF at baseline. 
Results: Compared to patlicipants in sinus d'tylhm, those wtth AF wem 
mole likely to have an e[eCtion tractlon (EF) ~20% (23 rs. 18%) or N~rtA 
class Ill/IV symptoms (22 rs. 12%). Patients with AF more fmquentty used 
anticoagulants (34 rs. 9%). antianhylhmics (23 rs. 17%), digoxin (at vs. 
30%) or diuretics (59 vs 42%) [all P <_ 0.001 ]. Despite multwanate adjustment 
for NYHA class, EF, pnor MI, antiarrhythmic use and ofher variables, AF 
remained tndependentty associated w~th all-c~uso mortatity (RR 1.34; 95% 
CI 1.11-1.61; P = 0.002) and death trom progressive pump failum (RR 1 42: 
95% CI 1.10-1.87: P = 0.01). There was no assoc~ation of AF with the r~sk 
for arrhythmtc death (RR 1,11; 95% C1074-1.67; P = 0.63). 
Concluston: After ad]usting for baseline d~fferences. AF remaJned inde- 
pendently associated with both the nsk of total modatity and pump failure 
death. Thus, AF may have an adverse effect on LV function. 
~-~ New Echocardlographic Advancu for 
Unders tand lng  and  Thorapy of Comnary 
Ar le ry  Dlsu~e 
Tuesday,  March 31, 1998, 400  p .m, -5 ;30  p,m, 
Georg la  World Congmss  Center ,  Room 257W 
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rtl~lo 81so I~roduced Fol!ow!ng Thmmbuo 
Dllmptlon by Pm/luormmrbop ~ontalùhql 
Mlcrobubb lu  Voraus Uroklnalm In ~ Pre len~e of 
Low Fr~uen~y Ul l ra lmùnd 
T. Po!ler, O, Knc~feld, S. Li, T, Bronah, U~fY  of N~rask~ M~J~cal 
Center, ~ Nebraska 
Ba~groun~ lntmvenous pedluoroca~on ex~ tBoeaateat ¢ le~ at, 
btJn~n (PE5DA) mlcrobubbles (MB) have been ehown, by them~e/ve~, to
pm~km~e intravasct+tar nenal thrombue, ~sn£ption in the pmsenae of Iran. 
scutaneous Iow ~ncy  ultrasOund (LFU$) W~th efficacy s~milm to ma! 
aChHP,/I~O ~ |h~yt lC  t~~ ('rA). ~ pui, pose of thia p ~  was 
t~ ae{ermme fflfferanoas In the mecl~anmm for PESDA-mediate¢l thrombus 
d~S~ when compare~ to TA. 
MetttO~~: Fresh veneus human t~rOmbi (@ 2 houm, mean we~g~t 102 ~- 
0.22 gramS) hOrn 6 healthy ~~lunteers wem expOsed to LFUS (20 k|lOhe~z) m 
tt~e presence o! eflher I ml of PESDA or t m! (5000 uni!s) ol urokinase (UK). 
The perceof of clof dmn~~n (%CD) was measured as wem D-emmr tevem 
(D.d) anä resm'um mmmbart~e sme (ZmaPlus/L'~yze+) m the m~m'wta~ 
Resutl~- %CD wtlh 1 ml PESDA tended to be h~gher than that a¢tllevl~ 
w~th 5000 unrls U~ (42 ± 22% PESDA ± US; 29 ± 16% UK + US; p = Oll). 
tevels wem all >250 noßml m the supemata~ of thromb~ exposeO to UK 
. US. hut wem al| ~ 250 hg/tal m UK * PESDA samptes (p « 0.005). 
Residual med~an m~roparttcle ~ze was 244 nanometers (nm) tor UK • 
LFUS and 320 nm for LFUS + PESOA (lange 197-462 nm: p > 0.05). 
Conctusmn: We coP, clu~e thet LFUS. PESDA alone produces an equrv- 
alent degme of human thrombus aßmrupt~ as TA in the presence of LFUS 
There Is no fibnnotyt~c ~tmn with PESDA MB-mediated clot resolutm~, 
sugges~ng mamPragme~ltat~on as Ihe mecha~lism. The res~dual padicle sizes 
produced by ctot ~smption w~h PESDA + LFUS, however, am am < I micron, 
wbich shouta not fead to distal microvascular bed embol=. 
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~- -~ Passive Acousttc ~~aginc .for Non.tnvasive 
Oetection and Local izatmn of Coronary Artery 
Disease: Detectlon Thmshold In an In-Vltro Model 
G E Pete~on, MS Hardee, A. Wang, K. Kisslo, B Macrum, TM. Bashom. 
J.K. Hamson. Duke UmverSdy M£,<:lJcal Center, ~urt~m, Norfh Carohna, 
USA 
Passrve aceusttc rmagmg using high f+deilty sound Imnsducers m a novel 
method !hat holds potemml for diagflomng coronary ahery les~ons noninva- 
slvety. To deterrrùne the thraslxdd for detectmg and Iocalizlng the shear ware 
energy cat,~=d by turOulent flow thmugh a stenosis, a 3 mm diameter sl~M¢ 
tube wttll stenose$ of varylr~g severlty (25, 50, 62. 75. 82 and 90% ~a111~ef 
5termsi5) was m~bedded in a gel interface to the transducers. Consta~ flow 
through the tubing was prov~e~ by 120 mm Hg pressure while acousflc 
imagmg was perfofmed. For all stenoses (except 82% and 90%) tmagmg 
was perfom~ed at flow rates of 50, 75 and 100 cc/min, The hlghest flow rate 
obtainable for the 82% stenosis waS 75 ccJmin, and tor the 90% stenos~s 
was 21 c~mm. 
Results: Detect~on of turbulence by the acoustic sensor arT~y was de- 
pendent on the percent stenosi$ and the flow rate AcOust[c signals could 
be detectc~l and Ioaalized for stenoses between 75% ancl gO% at flow rates 
as Iow as 13 cctmin. The 62% stenosas was detected at a flow rate of 100 
ccJmin, Du'- not at 50 or 75 cc/min. Stenoses ~50% wem acoustically sdent. 
regardtess ot fiow rate. 
Conclusion: Thls in-vitro model of coronan/stenosis demonstrates !hat 
shear wave energy pmduced b¥ turbulent flow can be detectea and localized 
by passive acousttc imaging for stenoses .50%. This new technol~:Jy holds 
prom[se for the non-invamve detection and localization of coronary disease. 
